Oxford Supply Limits Triptans
Defines quantity-per-copayment and home-delivery ceiling limits for specified triptan products and the clinical criteria under which requests exceeding the limited amount may be approved for Oxford members effective 1/1/2026.
Effective Date set for Oxford: 1/1/2026 and program versioning to 10/2025 noted in history.
Policy summary
Policy: Oxford Supply Limits for Triptans (Program 2025 P 1110-13) — Effective 2026-01-01. Triptans (listed products such as Imitrex nasal/injection, Onzetra Xsail, Tosymra, Zembrace SymTouch, zolmitriptan ODT, Zomig nasal spray) are approved for the acute treatment of migraine with or without aura and are not intended for prophylactic use or for management of hemiplegic or basilar migraine. The policy defines per-copayment quantity limits and ceiling limits (different for retail and home delivery) and establishes clinical criteria for approving quantities above the standard copayment/coinsurance limits for Oxford members.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.